Gilead Sciences, Inc. $GILD Position Decreased by Brown Advisory Inc.

Brown Advisory Inc. reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 256,539 shares of the biopharmaceutical company’s stock after selling 17,362 shares during the quarter. Brown Advisory Inc.’s holdings in Gilead Sciences were worth $28,442,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Gilead Sciences in the second quarter valued at $2,150,268,000. Price T Rowe Associates Inc. MD raised its position in shares of Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares during the period. Nuveen LLC purchased a new stake in shares of Gilead Sciences during the first quarter valued at $620,415,000. Invesco Ltd. boosted its position in shares of Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after purchasing an additional 3,394,330 shares during the period. Finally, Kingstone Capital Partners Texas LLC purchased a new position in Gilead Sciences in the 2nd quarter worth about $238,083,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have commented on GILD shares. Wolfe Research upped their price objective on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, October 23rd. Sanford C. Bernstein restated an “outperform” rating on shares of Gilead Sciences in a research report on Monday, November 3rd. Needham & Company LLC lifted their price objective on shares of Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Citigroup increased their target price on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $130.65.

Insider Activity

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the sale, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at $69,389,826.17. The trade was a 1.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the transaction, the insider owned 107,193 shares in the company, valued at $13,491,310.98. This represents a 20.71% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 135,757 shares of company stock valued at $16,616,127. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Trading Down 1.1%

Gilead Sciences stock opened at $121.22 on Friday. Gilead Sciences, Inc. has a 12 month low of $88.57 and a 12 month high of $128.70. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The stock has a market cap of $150.40 billion, a P/E ratio of 18.79, a P/E/G ratio of 0.67 and a beta of 0.32. The company’s fifty day simple moving average is $120.94 and its 200-day simple moving average is $115.29.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the previous year, the company posted $2.02 earnings per share. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.